Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers

Par Pharmaceutical Sued by Horizon Over Duexis Generic

Par Pharmaceutical Cos. was sued for patent infringement by Horizon Pharma Inc. over a generic version of the drug Duexis, used to treat arthritis.

Horizon, based in Northbrook, Illinois, contends Par plans to market a copy of the drug before two U.S. patents expire in 2026, according to a complaint filed yesterday in federal court in Wilmington, Delaware.

Unless a judge stops the alleged infringement, “Horizon will be irreparably harmed,” the company said in court papers.

Gross sales for Duexis in the third quarter of 2012 were $3 million, Horizon said in a Nov. 13 statement.

Stephen Mock, a spokesman for Woodcliff Lake, New Jersey-based Par, didn’t immediately return a phone call seeking comment on the lawsuit.

The case is Horizon Pharma v. Par Pharmaceutical, U.S. District Court, District of Delaware (Wilmington).

To see the patents in the lawsuit, click: 8,309,127 and 8,318,202.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.